Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 13/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2774341 | 0.90 | CCR1 (0.52) | CCR1KMT2AKCNH2LMNATSHR | |
| SCHEMBL2773563 | 0.82 | CCR1 (0.52) | CCR1KMT2AP2RY12KCNH2LMNA | |
| SCHEMBL2774900 | 0.82 | CCR1 (0.55) | CCR1KMT2AKCNH2LMNA | |
| SCHEMBL2775990 | 0.82 | CCR1 (0.47) | CCR1KMT2AP2RY12KCNH2LMNA | |
| SCHEMBL2774870 | 0.81 | CCR1 (0.52) | CCR1KMT2AKCNH2LMNATSHR | |
| SCHEMBL2777378 | 0.81 | CCR1 (0.52) | CCR1KMT2AP2RY12KCNH2LMNA | |
| SCHEMBL2774241 | 0.81 | CCR1 (0.52) | CCR1KMT2AKCNH2LMNATSHR | |
| SCHEMBL2777112 | 0.81 | CCR1 (0.52) | CCR1CACNA1BKMT2AKCNH2LMNA | |
| SCHEMBL2779075 | 0.80 | CCR1 (0.53) | CCR1KMT2AKCNH2LMNATSHR | |
| SCHEMBL2774278 | 0.80 | CCR1 (0.51) | CCR1KMT2AP2RY12KCNH2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2258697-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258697-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | F12, F2, C3AR1 | CCR1 1428/4885CACNA1B 1439/4885KMT2A 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.